US2018216077A1PendingUtilityA1

Differentiation of human ips cells to human alveolar type ii via definitive endoderm

Assignee: UNIV YALEPriority: Sep 25, 2012Filed: Feb 26, 2018Published: Aug 2, 2018
Est. expirySep 25, 2032(~6.2 yrs left)· nominal 20-yr term from priority
C12N 2501/16C12N 2501/415C12N 2533/52C12N 2533/70C12N 2501/115C12N 2533/54C12N 2501/11C12N 2533/50C12N 2501/119A61K 35/42C12N 5/0688C12N 2501/117C12N 2533/90C12N 2506/45A61P 11/00
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compositions and methods for generating populations of tissue precursor cells from pluripotent cells, and preferably induction of stem cells into definitive endoderm to generate anterior foregut endoderm from pluripotent cells. The anterior foregut endoderm cells can then be differentiated into an alveolar epithelial type II cell.

Claims

exact text as granted — not AI-modified
1 - 11 . (canceled) 
     
     
         12 . A population of lung cells produced by a method of differentiating a stem cell into a lung cell, the method comprising: a) inducing a stem cell into a definitive endoderm cell; b) inducing the definitive endoderm cell into an anterior foregut endoderm cell; c) inducing the anterior foregut endoderm cell into a lung cell, thereby differentiating a stem cell into a lung cell. 
     
     
         13 . The population lung cells of  claim 12 , wherein the population is at least 95% of cells exhibiting an alveolar type II phenotype. 
     
     
         14 . The population of lung cells of  claim 13 , wherein the alveolar type II phenotype is expression of an alveolar type II cell marker selected from the group consisting of SPC, Mucin-1, SPB, CD54, and any combination thereof. 
     
     
         15 . The population of lung cells of  claim 12 , wherein the population comprises genetically modified cells. 
     
     
         16 . The population of lung cells of  claim 12 , wherein the cells are genetically modified to express a therapeutic gene. 
     
     
         17 . The population of lungs cells of  claim 12 , wherein the cells resemble freshly isolated human primary alveolar type II cells. 
     
     
         18 . A method of alleviating or treating a lung defect in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a composition comprising a population of lung cells produced by a method of differentiating a stem cell into a lung cell, thereby alleviating or treating said lung defect in said mammal, wherein the differentiation method comprise: a) inducing a stem cell into a definitive endoderm cell; b) inducing the definitive endoderm cell into an anterior foregut endoderm cell; c) inducing the anterior foregut endoderm cell into a lung cell, thereby differentiating a stem cell into a lung cell.

Join the waitlist — get patent alerts

Track US2018216077A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.